illicit drugs. He had not noted any peri-orbital or leg edema, shortness of breath, chest pains, hematuria, or urinary symptoms. His only medication was fosinopril, 10 mg orally each day.
Patient 2 of the left kidney. A diagnosis of solitary functioning kidney
A 5-year-old white girl presented 17 years ago with an 8-was made.
month history of relapsing nephrotic syndrome. The first two The patient was treated with dietary protein restriction and episodes were steroid-sensitive, but subsequent relapses were an angiotensin-converting enzyme (ACE) inhibitor. At routine steroid-dependent, and she was admitted for renal biopsy. Labfollow-up at age 19, the proteinuria had increased to 3.7 g/24 oratory tests revealed normal serum creatinine (0.8 mg/dL), hr, and he was referred for further evaluation. The medical hypoalbuminemia (0.8 g/dL), proteinuria (2 g/24 hrs), negahistory was significant for a bilateral inguinal hernia repair at tive ASO titers, and normal complement levels. Physical exage 10 months, and a poorly documented history of vesicoureamination showed 3ϩ edema, and her blood pressure was teral reflux as a child. The family history was significant for 120/70 mm Hg. microhematuria detected in the father three months prior to
The renal biopsy showed no segmental sclerosis in the 23 this evaluation, a maternal grandmother with hypertension, glomeruli sampled. Immunofluorescence studies were negative, and a paternal grandfather with diabetes. There was no family and electron microscopy showed extensive foot process effacehistory of visual abnormalities or hearing loss. No hypertension ment. An initial diagnosis of minimal change disease was made. had been noted at regular follow-ups. The patient had gained
Corticosteroid treatment was continued with no response even 25 pounds over the previous 18 months. A college student, he at a higher dose (40 mg daily). Addition of a six-week course worked part-time in an ice cream store. He had smoked for of chlorambucil resulted in remission (serum albumin, 4.3 g/dL; one month one year previously and did not drink alcohol or use proteinuria, 420 mg/24 hr). She remained in remission for 18 months and had a normal serum creatinine (0.3 mg/dL) when she was 7 years old. She then had a relapse following an upper thy. Subsequent studies of the first native-kidney biopsy specimen demonstrated glomerulomegaly, with glomerular size 62% greater than age-matched control. and persistent proteinuria. In contrast, the second patient developed end-stage renal disease despite intervention when only the presence of glomerular hypertrophy heralded a sclerotic process. In the first patient, an ACE was in apparent remission from her nephrotic syndrome with inhibitor was given even though the patient was not hyperno edema when routine tests revealed that her serum creatinine tensive; in the second patient, even aggressive treatment was 6.0 mg/dL. A second renal biopsy showed advanced FSGS, with corticosteroids and chlorambucil failed to prevent typical of the idiopathic form (Fig. 2) . She rapidly reached endstage renal disease and was treated with peritoneal dialysis. progressive disease. I will discuss some of the possible Her course was complicated by multiple infections, and she mechanisms contributing to progressive glomeruloscleunderwent hemodialysis for six months. At age 11 years, she rosis, and also the possibilities of forestallment or even received a living related kidney transplant from her father.
DISCUSSION
regression of existing sclerosis.
She became pregnant at age 19 and developed preeclampsia Progressive renal disease historically has been considwith proteinuria and hypertension. Her serum creatinine was ered an inexorable, relentless process. Based on classic 1 .2 mg/dL after delivery of a healthy full-term baby boy. One studies from more than 20 years ago, straight-line regresyear later, she had an episode of acute rejection, which responded to increased immunosuppression with a return of the sions with negative slopes of the reciprocal of serum serum creatinine to baseline. A renal biopsy showed tubulitis creatinine have been used to predict the length of time superimposed on mild-to-moderate chronic transplant neuntil individual patients reach dialysis, transplantation, phropathy. The serum creatinine was stable one year later, but or death [1] . Recent studies indicate that it is time to it increased to 4.1 mg/dL one year ago. A repeat biopsy of the reassess this grim picture of progression [2, 3] . graft showed chronic transplant nephropathy with glomeruloClassic studies, both in animals and in humans, have sclerosis due to transplant glomerulopathy, without evidence shown that not only ACE inhibitors [3] , but also other of recurrent idiopathic FSGS. She was enrolled in a clinical intervention trial for treatment of chronic allograft nephropatherapies that normalize blood pressure, slow the rate of progression of renal failure over the long term. We have degree of total sclerosis and any of these hemodynamic variables in individual glomeruli. Thus, additional nonachieved resolution of established sclerosis in experimental models [4, 5] . Remarkably, recent studies have hemodynamic factors likely contribute to sclerosis.
We resurrected an old model of injury, ureteral diverindicated that resolution is also possible in humans with diabetic nephropathy. Repeat renal biopsies after pancresion, to examine progressive injury at the single glomerular level [12] . For this model, the ureter of one kidney atic transplant in patients with pre-existing diabetic nephropathy showed regression of mesangial expansion, is diverted into the peritoneum with partial ablation of the contralateral kidney; marked glomerular hyperperfumore patent glomerular loops, and a proportional decrease in tubulointerstitial fibrosis over a 10-year period [2] . sion and hyperfiltration, and increased glomerular pressure ensue. In our studies, these changes were accompaMechanisms of progression nied by only minimal glomerulosclerosis and minimal glomerular enlargement. In contrast, in the 5/6 nephrecTo effect regression, not only must mechanisms of progression be dampened, but remodeling of the existing tomy model (which results in glomerular hyperfiltration and hypertension comparable to the ureteral diversion sclerosis also must take place. Hypertension is a key mechanism associated with progression. Hypertension accelmodel) marked glomerular enlargement occurred and was closely associated with glomerulosclerosis. These two erates progression of chronic renal disease in humans, whether it results from or causes the renal disease. Imparameters, glomerular enlargement and sclerosis, were closely correlated at an individual glomerular level in a portantly, intraglomerular pressure can be modulated differentially from systemic blood pressure. The potenbiphasic distribution. We noted a positive correlation of glomerular enlargement and sclerosis at early phases of tial impact of local glomerular hemodynamic changes on sclerosis has been extensively studied in the Munichsclerosis (that is, as much as 50% of the tuft involved) and a negative correlation as the glomeruli progressed Wistar rat because this model has superficial glomeruli that can be directly punctured to measure glomerular to end-stage sclerosis [12] . The effectiveness of ACE inhibitors in ameliorating blood pressures and flows. As is well known, the remnant kidney model, in which 5/6 of the total renal parenchyma sclerosis in the remnant kidney model was associated with inhibition of glomerular growth. This relationship is removed, results in progressive hypertension, proteinuria, and matrix expansion; focal segmental glomeruloconfirms the correlation between glomerular growth and sclerosis [13] . However, ACE inhibition was not equally sclerosis ensues that mimics progressive injury in humans [6] [7] [8] . Anderson et al showed that ACE inhibition coneffective at all stages of fibrosis; progressive deterioration continued in glomeruli with more advanced sclerofers superior protection against progressive sclerosis compared with non-ACE-inhibitor antihypertensive treatsis, whereas progression was inhibited in glomeruli at earlier stages of sclerosis. These findings suggested that ment in this model [9] . Although both interventions normalized systemic pressures, only ACE inhibition dedifferent mechanisms were at work among the heterogeneously affected glomeruli, with different potentials for creased glomerular pressures, which remained high when systemic blood pressure was controlled to a similar deresponse to treatment. Our next step was to determine whether glomerular gree using antihypertensive medications other than ACE inhibitors, that is, "nonspecific therapy." This led Brenhypertrophy was linked with sclerosis in humans and whether that hypertrophy is an early sign of impending ner's group to postulate that increased glomerular capillary pressure is a key mediator of progressive renal sclerosis. We analyzed data from three pediatric patient groups: patients with initial biopsies consistent with minisclerosis in a self-perpetuating vicious cycle, whereby nephron loss due to sclerosis further increases flow and mal change disease and with a subsequent clinical course and second biopsy consistent with this diagnosis; a secpressures in the remaining glomeruli, thus augmenting and perpetuating injury [6, 9, 10]. We performed serial ond patient group with similar initial biopsies and subsequent overt progression to focal segmental glomerulosclemicropuncture studies in the same model to investigate whether hemodynamic derangement predicts the ultirosis (FSGS); and a third group of age-matched controls [14] . Today's second case was one of the index patients in mate severity of sclerosis in those same punctured glomeruli. When the rats were sacrificed, the glomeruli that this study. Initial biopsies revealed significant glomerular enlargement in patients with progression to focal seghad been micropunctured in vivo were identified, processed, and histologically assessed for sclerosis. The sclemental glomerulosclerosis, whereas patients with a subsequent clinical course and a second biopsy consistent rosis indices for the individual glomeruli then were correlated with either maximum single-nephron glomerular with minimal change disease showed normal glomerular size. Similarly, in adults with FSGS, glomeruli were filtration rate (GFR), glomerular pressure, or average values for these parameters as assessed by repeated milarger than in those with minimal change disease [14] . These findings have now been confirmed both in pediatcropuncture in these very same glomeruli over the preceding weeks [11] . We found no correlation between the ric and adult populations [15] .
Glomerular hypertrophy is linked with development it is likely that complex genetic traits modulate the response of glomerular cells to pathogenetic stimuli. Mice of sclerosis in other human diseases as well [15] . Abnormal glomerular growth in humans occurs with diabetes, with reduced nephron number because of a radiationinduced mutation that results in approximately 50% nephhypoxia (as in cyanotic heart disease, sickle cell disease, and obesity-associated sleep apnea), and limited renal ron reduction in association with oligosyndactyly (Os ϩ/ϩ ) developed severe glomerular enlargement and sclerosis mass (as in transplantation, extensive removal of renal mass, and unilateral renal agenesis, a risk factor present when this abnormality occurred on the sclerosis-prone ROP genetic background, but not in the sclerosis-resisin today's first patient). All these conditions also have been associated with lesions of FSGS. The close associatant C57 strain [18] . Glomerular hypertrophy was proportional to reduction of nephron mass in the former tion between glomerular enlargement and glomerulosclerosis likely reflects the actions of multiple factors strain. In contrast, a threshold for glomerular size was observed in the C57 mice. The interplay of genetic backon glomerular cells, with responses of increased matrix, hypertrophy, and proliferation often occurring in conground and response to injury is also well recognized in humans, in whom only approximately 40% of patients cert. Thus, increased glomerular size is a sign of a growth response to factors that often also induce increased mawith type-1 diabetes mellitus develop diabetic nephropathy [19] . trix accumulation, the hallmark of sclerosis. In human diabetes and idiopathic FSGS, increased glomerular size Age at onset of injury also modifies the kidney's growth response to renal ablation. Animal data indicate that precedes development of the sclerotic lesions. Interestingly, a recent genetic analysis of children with nephrotic increased sclerosis in the young cannot be explained by hemodynamic factors or glomerular size, but rather syndrome found that FSGS patients have a higher prevalence of the ACE deletion (D) polymorphism, compared might be related to factors unique in the young maturing kidney, which is characterized by centripetal growth and to the insertion (I) polymorphism, when compared with patients with minimal change disease [16] . This D allele differentiation [20] . Uninephrectomy in healthy adults produces no significant sequelae. Several follow-up studhas been associated with higher activity of the renin-angiotensin system (RAS), and this heightened activity might ies of renal transplant donors as well as individuals nephrectomized secondary to trauma suggest a benign course influence both renal growth and scarring responses. These findings suggest that minimal change disease and FSGS after unilateral nephrectomy [15, 21] . However, more extensive loss of renal mass in adult patients with bilatare distinct entities from the onset.
In vivo and in vitro experimental evidence points to eral tumors resulted in an increased incidence of FSGS in the remnant kidney [22] . In contrast, removal of one the capability of many cytokines to promote growth of glomerular cells and also to increase extracellular matrix kidney in children, for example, because of Wilms' tumor, has somewhat more ominous consequences: renal formation, thus promoting sclerosis as well as growth. Recent in vitro data based on sophisticated microchip growth was most marked in patients who had surgery at a younger age, and increased kidney growth was associated gene array analysis demonstrate that the early fibroblast response to growth factors includes a linked response of with microalbuminuria, which developed in 11 of 34 patients [23] . Likewise, patients with unilateral renal agenegenes implicated in cell division, wound healing, and angiogenesis [17] . These findings indicate tight linkages sis have a significantly increased risk of proteinuria (19%), hypertension (47%), and renal insufficiency (13%), and among growth, differentiation, and wound healing/ remodeling responses.
death was ascribed to renal disease in 6 of 157 in a large series [24] . Stimuli that have been shown in experimental conditions to promote growth and glomerulosclerosis include These findings suggest that the number of remnant nephrons in the congenital solitary kidney in fact might loss of renal mass; high-protein or high-salt diet; various hormones such as growth hormone, insulin-like growth be decreased (hypogenesis) and thereby represent a more severe form of reduction in nephron population factor, androgens, and glucocorticoids; and vasoactive molecules such as angiotensin II (Ang II) or endothelin than unilateral nephrectomy. The possibility that the remnant glomeruli of the congenital solitary kidney are [7, 15] . Hypertrophic stimuli accelerate sclerosis, and interventions that dampen glomerular hypertrophy also under greater hypertrophic stress is indeed supported by quantitative morphometric studies. The volume of each often ameliorate glomerulosclerosis. The latter include low-protein, low-salt, or low-phosphate diet, ablation of glomerulus in solitary kidneys was found to be five to six times normal, a value close to that found in oligoandrogenic effects by castration, antagonism of growth hormone with the somatostatin analogue octreotide, gemeganephronia, an extreme condition of decreased nephron number [25] . Decreased nephron number has netic defects in growth hormone, and inhibition of angiotensin or endothelin.
been postulated to occur secondary to low birthweight [26] . Lower nephron number has been postulated to Hypertrophic response and subsequent development of sclerosis are dependent on the genetic background, so increase the risk of renal disease and to be the mecha-nism whereby individuals with low birthweight have an The glomerulus is a unique structure with complex interactions of endothelial, mesangial, and epithelial cells in increased incidence of progressive renal disease in adulthood [26] . These fewer nephrons are postulated to be forming the filtering capillary loops. Glomerulosclerosis is defined as a combination of increased matrix and oblitunder greater hemodynamic stress that contributes to progressive sclerosis. I find it interesting that glomerular eration of the capillary lumina. Increased matrix accumulation is the result of extracellular matrix synthesis in size in normal African Americans is larger than that in whites and possibly reflects smaller nephron number excess of degradation. To accomplish regression of sclerosis, these pathways have to be modified and excess [27] . This finding could contribute to the increased incidence of end-stage renal disease in African Americans extracellular matrix degraded. Most challenging is the remodeling of obliterated capillary lumina (Table 1 ). compared to whites. Mechanisms other than hemodynamic stress that could underlie these differences in norDepending on the cell types involved, injured cells have to be replenished, repaired, or deleted to regenerate or mal glomerular growth and that also relate to an increased incidence of end-stage renal disease include restore capillary loops that might result in glomerular filtration (Fig. 3) . Three main obstacles have to be overfunctional polymorphisms of genes that are involved both in renal and glomerular development and that concome. First, the net loss of endothelial cells must be resolved via regeneration of endothelial cells; second, tribute to amplified scarring mechanisms, such as the renin-angiotensin system.
there is variable mesangial cell proliferation that evolves into the sclerotic, acellular lesion, and mesangial cells In addition to the key roles of hypertension and growth factors on extracellular matrix accumulation and scleromust regrow; finally, the visceral epithelial cell has limited growth capacity. New glomeruli cannot be generated sis, multiple other mediators have been associated with glomerular sclerosis [7, 8, 28] . The detailed discussion after full-term birth in humans, so regeneration of open loops has to occur by new capillary loop growth within of these mediators is beyond the scope of this Forum, but these factors include, but are not limited to, hyperlipinjured glomeruli, with resorption of the sclerosed segments within that glomerulus. Thus, the restoration of idemia, proteinuria, reactive oxygen species, the diabetic milieu, and infiltrating macrophages. The pattern of speopen capillary loops is not a return to its original structure. We postulate, rather, that "regression" is mediated cific factors activated likely depends on the type of initial injury, the age of the patient when the insult occurs, and by new growth of capillaries that take the place of the sclerosed, reabsorbed segments. Evidence in humans and complex genetic factors, all of which modulate the process of sclerosis.
animals indicates that glomerular growth after injury can indeed be achieved by lengthening or branching of the Potential regression capillary loops [32, 33] . The biologic potential of each of these processes in the glomerulus indicates that reConsidering this multiplicity of mediators of sclerosis, one can ask whether it is possible to halt or even reverse modeling and regression of glomerulosclerosis are theoretically possible. Emerging data show that they can be these destructive processes within the kidney. Regression of sclerosis, however, already has been accomplished in accomplished in practice as well.
Cell growth versus apoptosis and differentiation. Alcardiovascular disease [29, 30] . Studies in animals and humans show feasibility of regression of atherosclerotic though the sclerotic glomerulus appears acellular and "dead," cell turnover continues; thus, even at advanced plaque, regression of coronary artery disease, and regression of left ventricular hypertrophy and fibrosis, all with stages of sclerosis, modulation of cell growth and consequent regeneration can occur [34] . Glomerular growth associated improved cardiovascular function. Groundbreaking studies from 1970 showed resolution of atherois influenced by numerous cytokines and hormones, including Ang II. The angiotensin II type-1 (AT1) receptor sclerotic lesions in coronary arteries when rhesus monkeys were given diets that decreased serum cholesterol mediates cell hypertrophy and/or hyperplasia, and is widely expressed in the kidney including in mesangial, [30] . Even severe fibrotic lesions that consisted of vascular smooth muscle cell proliferation, augmented fibrosis, glomerular visceral epithelial, endothelial, and vascular smooth muscle cells [35] [36] [37] . Cell growth after injury frecollagen, and abnormal endothelial reactivity improved. Myocardial fibrosis is also remediable: the increased quently is accompanied by increased apoptosis (Fig. 3 ). Apoptosis is induced by a variety of factors, including amount of left ventricular mass due largely to collagen accumulation in the untreated spontaneously hypertenAng II. This effect of Ang II is mediated by the AT2 receptor. This receptor is up-regulated in vascular smooth sive rat was reduced with an ACE inhibitor. This improvement was associated with augmented proteolytic muscle cells in neointima at sites of injury. Because overexpression of the AT2 receptor results in decreased vasactivity, which might have played a mechanistic role in the remodeling [31] . cular lesions after injury, it is likely that AT2 has a role in remodeling and repair [37, 38] . Pharmacologic But results from heart, coronary artery, and aorta cannot be directly extrapolated to the sclerotic glomerulus.
inhibition or absence of the AT2 receptor in null mutant mice, with resulting deficient apoptosis after injury, incells was associated with sclerosis in the 5/6 nephrectomy model [41] . Numerous growth factors modulate these creases fibrosis in rodent models of renal and cardiac fibrosis [39, 40] . Apoptosis might be a healing mecharesponses [28] . Vascular endothelial-derived growth factor (VEGF) is an endothelial cell-specific mitogen pronism, eliminating injured cells with minimal stimulation of immune/inflammatory mechanisms and cytokines.
duced by glomerular visceral epithelial cells that specifically regulates physiologic and pathologic endothelial However, disproportionate apoptosis of cell types that cannot regenerate can have deleterious consequences. cell growth and glomerular permeability. Recent evidence implicates VEGF as a necessary survival factor for Mesangial and endothelial cells can readily proliferate and replenish after injury. In the anti-Thy-1 model of endothelial cells in vivo (abstract; Suga et al, J Am Soc Nephrol 10:561A, 1999), and inhibition of VEGF premesangial proliferation, endothelial and mesangial cells proliferate during the spontaneous resolution phase. But vented repair after anti-Thy-1 injury [42] . In contrast to the strong potential of mesangial and when angiogenesis was pharmacologically inhibited, repair failed (abstract; Kitamura et al, J Am Soc Nephrol endothelial cells to contribute to remodeling, the glomerular visceral epithelial cell is "growth challenged." This 9:501A, 1999). Similarly, excess apoptosis of endothelial lack of proliferation in the normal mature glomerular modulation of matrix can occur [52] . The matrix metalloproteinases (MMP) are a class of zinc-dependent protevisceral epithelial cell is accompanied by high expression of a cyclin-dependent kinase inhibitor, p27 kip1 [43] , which ases. Expressed in glomeruli, MMP-2 (gelatinase A) and MMP-9 (gelatinase B) have particular relevance to gloseems to be a rate-limiting step for the growth response of the visceral epithelial cell. Shankland recently sugmerular collagen remodeling. Both degrade collagen IV, a prominent component of glomerular basement memgested that either too much or too little proliferation of the visceral epithelial cell in response to genetic manipubrane, and also proteoglycan and fibronectin, components of mesangial matrix [50] . Several tissue inhibitors lation of p27 kip1 is detrimental to the glomerulus [44] . Inadequate growth of the visceral epithelial cell possibly of matrix metalloproteinases (TIMPs) also are present in glomeruli: TIMP-2 is produced in the glomerulus by gives rise to areas of dehiscence and insudation of plasma proteins, which progress to adhesions and sclerosis [45] . mesangial cells and is constitutively expressed, whereas TIMP-1 is up-regulated in response to numerous injuries. Recent data showing that another cyclin-dependent kinase inhibitor, p21, appears necessary for development TIMP-1 is induced by angiotensin in vitro and downregulated by TGF-␤; TIMP-2 is up-regulated by TGF-␤ of injury after 5/6 nephrectomy in mice suggests the crucial importance of cell growth responses in determinand contributes to increased extracellular matrix accumulation [53] . ing the whole kidney's response to injury [46] .
Cell growth also is associated with altered cell differen-A shift in balance of proteases and their inhibitors occurs during matrix expansion (Fig. 3) . Proteolytic actiation. The mesangial cell shows ␣-smooth muscle actin expression in sclerotic conditions, indicating a more myotivity decreased during progressive renal disease in rats, and expression of TIMP increased in the puromycin fibroblast-like phenotype [47] . Mature glomerular visceral epithelial cells normally express several markers, model of chronic renal disease. Conversely, protection from aging-induced sclerosis in female rats was associincluding Wilms' tumor (WT-1) tumor-suppressor transcription factor; a podocyte-specific tyrosine phosphaated with increased glomerular metalloproteinase activity compared with affected males [54] , and a shift towards tase, GLEPP-1; and synaptopodin. Dedifferentiation of visceral epithelial cells is linked to sclerosis in human proteolysis occurred during resolution of injury in the reversible anti-Thy-1 model of mesangial matrix expancollapsing glomerulopathy, a disease with severe collapse, sclerosis, and epithelial cell injury. There was loss sion [55] . Treatments that slowed disease progression in puromycin nephropathy also moderated changes in of expression of WT-1 and other differentiation markers associated with proliferation, and perhaps apoptosis, of protease gene expression [56] . Recent evidence has added PAI-1 to this array of the visceral epithelial cell in injured segments [48] . Recently, mutations of WT-1 resulting in abnormal splice matrix modulators in the kidney. Plasminogen activator inhibitor-1 inhibits not only fibrinolysis, but also proteolvariants have been associated with the development of FSGS; thus, WT-1 might not merely be a marker of deysis by inhibiting activation of plasminogen activators (PA). Plasmin can cleave most extracellular matrix prodifferentiation but also could play a role in normal control of epithelial cell function [49] .
teins [57, 58] , and both tissue-type (t-PA) and urokinase plasminogen activators (u-PA) play important roles in Matrix synthesis versus degradation. In addition to increased matrix synthesis, decreased extracellular matrix vascular remodeling, angiogenesis, and tumor metastasis [58] . Tissue-type plasminogen activator primarily affects proteolysis contributes to progressive renal disease [50] . Numerous growth factors have been characterized in fibrinolysis, whereas u-PA has less affinity for fibrin but avidly degrades matrix [58] . Normally present in very low terms of their ability to increase matrix synthesis, including the proto-oncogenes, transforming growth factor-␤ levels in the kidney, PAI-1 is expressed in vitro in many cells, including endothelial and visceral epithelial cells (TGF-␤), platelet-derived growth factor (PDGF), and vasoactive substances such as Ang II and endothelin [7] . [58, 59] , and is increased in settings of vascular injury, whether thrombotic or fibrotic [28] . Increased PAI-1 lev-TGF-␤ promotes extracellular matrix accumulation by increasing matrix production and possibly by decreasing els, whether due to the functional 4G/4G polymorphism of the PAI-1 gene promoter, or for other causes, are its degradation, in part by induction of plasminogen activator inhibitor-1 (PAI-1) [51] . Both PDGF-B and Ang associated with cardiovascular disease [60] . Diabetic patients with compound polymorphisms for both the PAI-1 II increase TGF-␤, and Ang II also promotes conversion of TGF-␤ to its active form. Plasmin might play a role in 4G and the ACE D allele, the latter of which increases renin-angiotensin system (RAS) activity, had increased this activation [51] .
In contrast to the extensive investigation of factors macrovascular disease [61] . The ability of TGF-␤1 to induce fibrosis also might relate to PAI-1: TGF-␤1 inpromoting matrix synthesis, modulators of increased matrix degradation, which could allow resolution, have duces PAI-1 to a greater extent than u-PA in cultured endothelial cells, and thus promotes fibrosis [62] . not been well characterized. Several proteases and protease inhibitors are expressed in the glomerulus; thus, Our data directly link local PAI-1 expression to sites of sclerosis, and decreased PAI-1 to resolution of sclerosis. anisms involved in regression of glomerulosclerosis. Spontaneous resolution of mesangial matrix accumulation Angiotensin II modulates fibrosis by direct effects of matrix and by activating other growth factors [7] . Also, occurs in the anti-Thy-1 model. At one day after antiThy-1 injection, matrix mesangiolysis is apparent; this is Ang II can induce PAI-1 directly, both in vitro and in vivo [63] [64] [65] , and inhibition of Ang II prevents this inducfollowed by increased matrix at one week, more increase at two weeks, and then restoration of normal morpholtion both in experimental models and in humans [66, 67] . Interactions between PAI-1 and Ang II thus could be ogy by four weeks, with attendant changes in cell proliferation and increasing metalloproteinase activity [55] . of primary importance in fibrosis. Conversely, inhibition of the RAS could promote remodeling of sclerosis by
Orloff et al demonstrated regression of matrix expansion in response to an intervention that cured diabetes in a decreasing PAI-1 and thus augmenting proteolysis. Angiotensin II and its hexapeptide metabolite, angiotensin rat model [75] . They assessed relative mesangial volume on renal biopsy specimens at six months after streptozo-IV, induce dose-and time-dependent increases in PAI-1 mRNA expression in vitro [63] . In vivo, this effect was tocin injection in the rat. Pancreatic transplantation was then done. Over the following one to nine months, mesmediated by Ang II and the type-1 receptor in the rat model [65] . Further, increased RAS activity mediated angial volume expansion decreased. Pancreatic transplantation also reversed matrix expansion when the aniby exogenous infusion of physiologic amounts of Ang II or by the presence of the ACE DD polymorphism (abmals were treated at the very late stage, after more than 20 months of diabetes, when mesangial volume was much stract; Brown et al, Circulation 92:1-552, 1995) increases PAI-1 levels in humans with no effect on t-PA [64] . more expanded. One must caution that these diabetic rat models do not show true sclerosis, but rather just mesInteractions of RAS and aldosterone. Recent data linking aldosterone to PAI-1 induction in vitro and in vivo angial matrix increase, and these mechanisms of regression therefore might not be applicable to diabetic huillustrate a further mechanism by which the renin-angiotensin system might augment sclerosis. Addition of aldomans. However, in the chronic puromycin aminonucleoside model, a true glomerulosclerosis model in which sterone antagonism to angiotensin inhibition resulted in greater resolution of glomerulosclerosis in animal studies capillary lumina are obliterated, regression of sclerosis with intervention with either an ACE inhibitor or lowthan did angiotensin inhibition alone [68] . Aldosterone antagonism alone also decreased vascular injury in the protein diet was suggested. In these experiments, cohorts of animals sacrificed at different time intervals were comstroke-prone hypertensive rat model [69, 70] . Aldosterone increases Ang II induction of PAI-1 in vitro, and pared. Progression occurred in almost all the untreated animals by 24 weeks. Animals treated from the onset PAI-1 plasma levels correlate with aldosterone levels in patients [71] . Our recent studies show that antagonism with ACE inhibition showed less sclerosis at 24 weeks compared with treated animals that were sacrificed at of aldosterone with spironolactone ameliorated the development of sclerosis in the nonhypertensive sclerosis 12 weeks [76] . The skeptic might argue that true regression is not absolutely demonstrated by these experimodel of radiation nephropathy. This finding was not linked to effects on blood pressure or proteinuria, but ments, as lesions were not compared in the same animals.
The relatively large number of animals studied at each was tightly associated with decreased PAI-1 [72] . Recent studies in humans have shown that PAI-1 plasma levels time point makes it likely that group results are applicable to the individual animals as well. We sought to directly and activity are reduced in response to an ACE inhibitor, but not to an angiotensin type-1 receptor antagonist confirm the possibility of regression in this nonhypertensive puromycin aminonucleoside model of glomer-(AT1RA). This effect was associated with an augmented decrease in plasma aldosterone levels in the ACE inhibiulosclerosis, comparing biopsy-documented to autopsydocumented sclerosis in the same rats [4] . Regression of tor-treated patients compared with those who received an AT1RA [73] . These findings provide linkage of aldosclerosis by late-stage intervention with an ACE inhibitor or AT1RA was indeed achieved. Sclerosis, however, sterone to possible fibrotic mechanisms and suggest that antihypertensive treatments might have to target both was very mild in this nonhypertensive model. We therefore examined whether regression could be achieved in the RAS and aldosterone in some settings for optimal regression of end-organ damage. a hypertensive model with more severe existing sclerosis, a situation more analogous to most human renal disease.
Evidence of regression. Inadvertent transplantation of kidneys with diabetic injury into nondiabetic recipients
Considering the evidence that nonhemodynamic mechanisms contribute to Ang II's effects on sclerosis, we demonstrated resolution of mesangial expansion in humans [74] . More recent data have shown that cure of postulated that higher doses of an Ang II inhibitor than those required to normalize blood pressure would have diabetes by pancreatic transplantation in patients with diabetic nephropathy also could reverse renal injury, a greater beneficial effect on sclerosis. We assessed the severity of glomerulosclerosis by renal biopsy at eight albeit over a long period [2] .
Experimental models shed light on some of the mechweeks after 5/6 nephrectomy in the rat [5] . Animals were then divided into groups that received no treatment, a closely associated with sites of glomerular injury, as assessed by serial action section morphologic analysis. In "normal" dose of an ACE inhibitor (that is, minimum dose required to normalize blood pressure), or a fourfold glomeruli, PAI-1 mRNA was localized to injured mesangial and endothelial areas, with focal expression in glohigher dose of the ACE inhibitor. Systemic and glomerular pressures were normalized by both ACE inhibitor merular visceral and parietal epithelial cells. Thus, autocrine effects are implicated, as these cells also express doses with no further hemodynamic effects at the higher dose. Sclerosis progressed in all untreated animals, with receptors for angiotensin (AT1 and possibly AT4 receptors). Minimal PAI-1 expression was seen in intact an average increase in the severity of sclerosis of 176 Ϯ 58%. Progression of sclerosis was significantly amelioglomeruli, whereas increasing levels of expression were present in sclerotic glomeruli or in glomeruli with a comrated in animals receiving the normal ACE inhibitor dose, with a mean increase in the severity of sclerosis of bination of sclerosis, mesangiolysis, and thrombosis. Treatment with AT1RA or an ACE inhibitor signifionly 49 Ϯ 17%. Remarkably, sclerosis was even further ameliorated and even regressed by the fourfold higher cantly inhibited the up-regulation of PAI-1 mRNA by Northern blot without affecting t-PA or u-PA expres-ACE inhibitor dose, with less sclerosis at autopsy than at biopsy four weeks previously in three of the five rats.
sion. No changes in the expression of other growth factors were associated with endothelial injury, including The AT1RA was similarly effective, achieving regression in one-half the rats (abstract; Nakamura et al, J Am PDGF, basic fibroblast growth factor, tumor necrosis factor-␣, and interleukin-1␤. At week 12, TGF-␤ mRNA Soc Nephrol 10:665A, 1999). Tubulointerstitial fibrosis regressed in parallel with glomerular injury. levels were moderately increased, and this increase was mildly attenuated by treatment with AT1RA or an ACE Possible mechanisms by which these higher doses of Ang II inhibition resulted in decreased sclerosis include inhibitor. TGF-␤ mRNA expression by in situ hybridization was diffuse, and no differences in mRNA expression inhibition of Ang II's ability to increase blood pressure and increase extracellular matrix synthesis, and inhibiwere apparent between irradiated glomeruli with and without morphologic lesions [67] . tion of other growth factors linked to Ang II, such as PDGF and TGF-␤. However, to decrease existing extraRenal sclerosis was prevented by treatment with either an ACE inhibitor or AT1RA. Irradiated animals treated cellular matrix accumulation, increased matrix degradation also must have occurred. Keeping in mind the direct with Ang II inhibitors showed even less sclerosis than did age-matched controls; this finding indicated that Ang II link between Ang II and PAI-1, we examined the potential role of PAI-1 in the regression of sclerosis. Sclerosis inhibition even might affect the matrix accumulation that accompanies the aging process. Amelioration of agewas similar at biopsy in both groups by study design, and was paralleled by similar PAI-1 glomerular protein related glomerular and vascular sclerosis also occurred in previous studies [4, 77] . We recently found that even expression. In individual glomeruli, PAI-1 staining correlated strongly with sclerosis (R 2 ϭ 0.734, P Ͻ 0.0001). existing age-related glomerular and vascular stenosis in the rat could be remodeled, with regression and deIn 5/6 nephrectomy animals without treatment, PAI-1 protein was intensely expressed at autopsy and localized creased collagen content induced by starting AT1RA treatment in aging rats. This remodeling was associated to sites of injury. In animals treated with AT1RA but not achieving resolution, PAI-1 expression remained promiwith decreased PAI-1 [78] . nent. In contrast, in those animals in which AT1RA proSummary duced regression of sclerosis, PAI-1 expression was virtually absent, with less staining than at biopsy in these All the data I have discussed today demonstrate that regression of biopsy-proven glomerulosclerosis can be same rats (P Ͻ 0.05). Rats with regression of sclerosis also had improved renal function, with lower serum creachieved in various experimental settings, including those germane to human disease in which moderate glomeratinine levels in AT1RA-treated animals versus untreated rats with 5/6 nephrectomy (1.16 Ϯ 0.12 versus ulosclerosis, proteinuria, and hypertension frequently are present at the time of diagnosis. Limited data show the 2.37 Ϯ 0.69 mg/dL), although hypertension and proteinuria were not significantly affected (abstract; Nakamura feasibility of regression of injury in human diabetic nephropathy. The potential importance of the renin-angioet al, J Am Soc Nephrol 10:655A, 1999). These findings implicate inhibition of PAI-1 by high doses of AT1RA tensin system in the spectrum of injuries leading to mesangial matrix accumulation and sclerosis is underscored or ACE inhibition and the resulting increased matrix degradation in regression of glomerulosclerosis.
by the effectiveness of therapies that aim to inhibit its manifold actions, including induction of PAI-1. UnderThe link of PAI-1 expression and sclerosis also was demonstrated in the radiation nephropathy model, a standing of interactions of the RAS and aldosterone with PAI-1, and of the dynamic control of cell proliferation, nonhypertensive model of early endothelial injury followed by late sclerosis [67] . Plasminogen activator inhibiapoptosis, and regeneration is now evolving. Ongoing studies will establish which of these recent provocative tor-1 mRNA expression by in situ hybridization was findings from animal models are relevant to human dis-PAI-1 presumed to be exerted directly at the glomerular level? eases and might lead to optimal therapies to forestall progression, and perhaps even induce regression, of sclerosis. The inhibitors can slow the progression of chronic renal dis-RALES trial might be an example of a beneficial effect eases, but it appears unlikely that by themselves they of reducing aldosterone. will be able to forestall progression in the majority of Dr. Fogo: Thank you for reminding me of that. This patients. Given the multiple effector mechanisms of rebenefit is not readily explained by the classic aldosterone nal injury, would you think that a multipronged approach actions. This is analogous to the change in understanding should be explored? of angiotensin effects. Fifteen to 20 years ago, only the Dr. Fogo: That would be the ideal way to approach classic actions of angiotensin, which related to sodium chronic renal disease. In the future, patients' genetic conand water homeostasis and blood pressure, were considtributions to risk factors will be considered and maybe ered. Angiotensin's actions are now recognized to be we will pre-emptively inhibit mechanisms that are likely manifold, as have the actions of the other factors we to be activated in the very early stages of disease. Not have discussed. Novel effects of aldosterone on fibrosis much direct evidence on therapeutic combinations is are now emerging. available. In one small study of eight patients with proDr. John T. Harrington (Dean, Tufts University School teinuria and IgA nephropathy, combined ACE inhibitor of Medicine): You talked about glomerular size versus and receptor antagonist therapy yielded higher antiprosclerosis in three groups: normals, patients with minimal teinuric effects without an additional decrease in blood change disease, and patients with focal sclerosis. Were the pressure [79] . We are embarking on animal studies to patients with minimal change disease and those with focal test the combination of high doses of both these drugs.
sclerosis studied at comparable times in the course of their Dr. Madias: I wanted to explore a bit further the disease? That is, did they have equal levels of proteinuria potential role of aldosterone in renal damage. You noted and renal function, or had the patients with minimal that both Ang II and aldosterone induce PAI-1. Accordchange disease cleared their proteinuria versus the paingly, I wonder whether there are observations on intients with FSGS who might still have had proteinuria? duction of PAI-1 in settings of increased mineralocorDr. Fogo: The pediatric nephrologists would be loathe ticoid but suppressed Ang II levels, such as the DOCA/ to biopsy a patient with minimal change disease but no salt model. proteinuria! These were all patients biopsied for clinical Dr. Fogo: It's difficult to establish such interactions reasons who had steroid-resistant or steroid-dependent because of the limitations inherent in measuring these nephrotic syndrome. The duration of proteinuria, the activities via serum levels rather than in the tissues. Denumber of relapses, the preceding treatments with stespite the absence of an elevated plasma renin activity roids and even, in some cases, slightly more aggressive in many patients, ACE inhibitors impart benefit. Also, therapy, were the same in both groups. In terms of those despite continued Ang II production during ACE inhibiinitial biopsies, none of them revealed sclerosis. Only tion through non-ACE mechanisms, the blood pressure later, as in our Patient 2, did the sclerosis develop. These remains controlled and the long-term beneficial effects are not the "standard" patients with minimal change of ACE inhibitors on GFR continue. In relation to aldodisease; we do not biopsy them, just as you don't biopsy sterone, the aldosterone effect on glomerulosclerosis a "typical" patient with diabetic nephropathy. does not seem to be related to hypertension, tubular Dr. Harrington: You discussed the production of exeffect, or sodium transport via the classic mineralocortitracellular matrix in detail. Is any information available coid receptor. Our experiments using knockout animals on the degree of apoptosis? Is it up-regulated, downdevoid of angiotensinogen showed that plasma potasregulated? What, if anything, can we do about it? sium in the absence of angiotensin can be a powerful Dr. Fogo: Apoptosis began to be studied with great stimulus to aldosterone activity [80] . When we removed interest in renal disease several years ago. We searched sodium and potassium from the animals' diet, they died intensively for apoptosis in animal models in glomeruli with hypotension and very low aldosterone levels. We that were undergoing sclerosis and found very little apostill don't understand the specific mechanisms for the ptosis. Dr. Vivette D'Agati's group published an abstract many interactions.
delineating apoptosis in human biopsy specimens (abstract; Szabolcs et al, J Am Soc Nephrol 5:844, 1994). Of Dr. Madias: Is the ability of aldosterone to induce course, proliferation as well as apoptosis were increased marked glomerulomegaly. The key, of course, is the history and the time course of what had happened to him. in proliferative forms of glomerulonephritis such as lupus and MPGN. Surprisingly, apoptosis also was present in These help to correlate morphology and clinical features and to make a clinicopathologic diagnosis. FSGS. Our own studies in rats have shown extremely low levels of apoptosis (unpublished data). Apoptosis is
In the second patient, the first biopsy did not show signs of sclerosis. The second biopsy revealed extensive a fleeting phenomenon, and determining its occurrence in a tissue section from the glomerulus is challenging.
sclerosis. There were no immune complexes. The morphology in the very advanced stage of sclerosis can make TUNEL staining is not completely specific, and morphologically apoptotic cells are rare in FSGS. The balance it difficult to discern the underlying cause. The nonsclerotic segments in this patient had no lesions other than of cell cycle regulatory mechanisms is very important. In virtually all settings in which we find increased proliffoot process effacement, and the sclerosis seen on light microscopy was consistent with idiopathic FSGS. Light eration, we also find increased apoptosis. Elegant summaries of many of these studies have been published microscopy of the transplant biopsy specimen disclosed segmental sclerosis, but she also had a basement mem- [44, 81] .
Dr. Andrew S. Levey (Chief, Division of Nephrology, brane abnormality of apparent splitting, that is, reduplication of the basement membrane. This lesion is characNew England Medical Center): I need a pathology lesson. My questions relate to correlations of pathology with teristic of transplant glomerulopathy and likely results from chronic endothelial injury. This injury causes etiology and mechanism of injury. In your description of the two cases, I see descriptions of three types of expansion of the lamina rara interna, which we visualized by electron microscopy. It is virtually certain that she has focal sclerosis. Patient 1's open renal biopsy shows focal segmental sclerosis and marked glomerulomegaly chartransplant glomerulopathy, with the segmental sclerosis due to this injury and not due to recurrence of FSGS. acteristic of secondary FSGS. Patient 2's renal biopsy demonstrates advanced FSGS typical of the idiopathic
The time course helps us make this diagnosis too. She had had her transplant for 10 years at that time. We form. The transplant renal biopsy from Patient 2 revealed glomerular sclerosis due to transplant glomeruloknow that recurrence of FSGS most often occurs within the first year, or even within the first month. In some pathy but no evidence of recurrent idiopathic FSGS. What's the size distribution of the glomeruli among these cases, recurrent proteinuria has started while the patient was still in the operating room receiving the kidney. lesions? And what are the correlations with progression or regression of these lesions?
In terms of glomerular size in various sclerotic lesions, it depends on the etiology. With unilateral renal ageneDr. Fogo: This is one of the fun and challenging areas in pathology: to recognize a lesion and then try to sis, the glomeruli are very large. In oligomeganephronia, the glomeruli are even bigger. In segmental sclerosis dissect it, distill it, and deduce its origin and prognosis. Saying that there is a lesion of glomerular sclerosis in a associated with sickle cell nephropathy, Dr. Bhathena has shown the largest glomeruli demonstrated in humans focal segmental pattern is only a description, and the description doesn't necessarily tell us what the underly- [82] . We have looked at recurrent FSGS in transplants. We chose our population carefully because an adult reing disease is. It just says that the scarring affects some glomeruli in a segmental fashion. We look very hard for cipient of an adult kidney normally has about a 30% increase in renal size and GFR over the first three indications that this could be a secondary rather than an idiopathic process, because the two conclusions have very months. The donor's remaining kidney undergoes the same kind of changes. So there normally is glomerular different treatment implications. It's very easy to arrive at a diagnosis in a patient who has sclerosis in a focal growth in kidneys transplanted into adults. We therefore looked at pediatric recipients of adult kidneys, in whom segmental pattern but IgA deposits as well. This lesion is chronic IgA nephropathy, and the sclerosis indicates glomerular enlargement generally doesn't occur. The patients who developed recurrence of FSGS had glomerua worse prognosis. The same holds true for sclerotic lesions in lupus or membranous glomerulonephritis or lomegaly preceding the onset of the sclerosis. The children who had FSGS or other diseases who did not in a healed crescentic glomerulonephritis-you can see the fibrocellular crescents or the immune complexes.
develop FSGS in their transplant had no glomerulomegaly [15] . We have not looked at the issue of transplant However, the secondary FSGSs that are not immunecomplex-mediated-such as those secondary to loss of glomerulopathy in the renal graft and glomerular size. Dr. Levey: To test the effects of agents that influence a kidney very early in childhood or during development, hypertension, or transplant glomerulopathy-are more all the mediators that you mentioned, of course you will need to carry out many clinical trials. But the clinical subtle lesions to analyze. In today's first patient, the biopsy findings that suggested a secondary FSGS intrial paradigm for progressive renal disease is unsatisfactory for comparisons of multiple agents because it recluded thickening of Bowman's capsule, periglomerular fibrosis, mesangial increase, very early sclerosis, and quires a long follow-up period. This problem reflects our lack of surrogate clinical markers for progression and some proliferator-activated receptor-␥ (PPAR-␥). We became interested in PPAR-␥ because it interacts with regression. Would you accept increases or decreases in urinary protein excretion as surrogate markers of pro-PAI-1 and angiotensin. We treated animals with troglitazone, a PPAR-␥ agonist, with an angiotensin-receptor gression or regression? Are there agents in animal models in which the effects on progression are separate from antagonist, or with triple therapy. Although the animals remained hypertensive when we gave them troglitazone, the effects on proteinuria?
Dr. Fogo: Proteinuria is a very good marker of disease. sclerosis was ameliorated, along with decreased PAI-1. There was no effect on progression or PAI-1 when blood It has even been postulated as a mediator of disease progression. Dr Harrington asked relating to patients who have relapsing minimal change disease, or who are steroid-resistant. However, some patients have proteinuria and do not have significant scarring, such as those with minimal change
What is the role of corticosteroids in the progression of renal disease? As you know, Diego Garcia in a progresdisease; this group can be either steroid-resistant or steroid-dependent. There are patients who develop sclerosion study suggested that corticosteroids accelerate progression in animals with 5/6 nephrectomy [85] . Do cortisis who typically don't have significant proteinuria, particularly African American patients with hypertension costeroids have any effect on PAI-1? Do you think that corticosteroids play a role in the progression from miniand renal insufficiency. In these patients, there might be a primary microvascular disease rather than a direct mal change to focal glomerulosclerosis in patients? Dr. Fogo: We ourselves have not pursued a corticocausal effect of hypertension in the sclerosis. Larry Hunsicker has very interesting unpublished data from the steroid/PAI-1 linkage. My colleagues Drs. Douglas Vaughan and Nancy Brown have in vitro studies in which multicenter collaborative study in type-1 diabetes looking at patients who were given an ACE inhibitor and they manipulated the PAI-1 gene and demonstrated a glucocorticoid-responsive element in the PAI-1 prowhose proteinuria did not respond to the intervention. The subanalysis of these patients revealed long-term promoter, and aldosterone's effect of increasing Ang II induction of PAI-1 also localized to this region [71] . There tection of GFR compared with patients with persistent proteinuria who were receiving other medications. This is potential linkage through this mechanism. We have not explored glucocorticoid-PAI-1 interactions in vivo. effect was dissociated from the effect on proteinuria. Thus, I believe that we cannot use proteinuria as the sole crite-
The difficulty comes in assessing the balance between potential benefit from the immune modulatory effects of rion for response to intervention. In most cases, it is a very useful reflection of injury at the glomerular level.
corticosteroids versus the potential pro-fibrotic effects. Dr. Madias: I want to return to the remarkable obserDr. King: Prior to the use of ACE inhibitors, it was well known that blood pressure reduction retards provation of regression of diabetic nephropathy following pancreatic transplantation. Why did it take so long for gression of renal failure. In your animal model of radiation nephropathy, you used an AT1 receptor blocker such a regression to occur? Dr. Fogo: It is likely that these patients didn't have or an ACE inhibitor. Have you used so-called "triple" therapy or other non-Ang II-manipulating drugs? Also, a rapidly progressing disease in the first place. It takes 15 years after the onset of diabetes for one to develop what is the effect on PAI-1?
Dr. Fogo: I think we need to have JNC VI standards the earliest stages of nephropathy. It takes several years for diabetic transplant patients to develop measurable for the rats! Within so-called "normal" pressure levels it seems, at least in diabetic patients, lower is better, and basement membrane thickening and mesangial expansion in the graft, and 6 to 8 years for the full-blown the best "normal" level of blood pressure is probably a lot lower in diabetics than it is in other patients. We glomerular lesion to begin to develop. If all we are doing is removing the pathologic impulse and not adding other didn't perform triple therapy experiments in the animals that received radiation. We have given triple therapy in treatments that could accelerate normal remodeling, this would be the time course you might predict by just reother animal models, such as animals that have undergone subtotal nephrectomy. In contrast to the amelioramoving the hyperglycemic environment and its effects on matrix accumulation. tion of sclerosis with ACE inhibitors with same blood pressure effect, triple therapy does not resolve progresDr. Madias: Are there known effects of advanced glycosylated end products on metalloproteinase activity sion of the glomerular sclerosis. Further, the effect on PAI-1 with these treatments is parallel to effects on scleand the proteolytic pathways? Dr. Fogo: The AGEs make the matrix proteins less rosis.
We have done some experiments in the 5/6 nephrecaccessible to metalloproteinases. I don't know whether they directly decrease the activity of the matrix metallotomy model looking at regression and comparing triple therapy with another intervention that targets peroxiproteinases. The animal models indicate that by decreas-ing AGEs, aminoguanidine could ameliorate scarring. New England Medical Center): I was intrigued by the effect of the high-dose ACE inhibition in the rat studies. The human studies, I understand, have not only been disappointing, but several patients have developed cresYou commented that the rats tolerated this well because their sympathetic and other vasoregulatory systems were centic glomerulonephritis that was ANCA-positive. Obviously, there are differences in rodents and humans.
intact. I think that a fair number of our patients would not tolerate it. Clearly, there are limiting side effects in Once we can find the genetic similarities, and model human diseases more carefully, we might be able to extraposome patients, particularly diabetics. Are efforts being made in drug development that would limit angiotensin late more directly and prudently from animals to humans. The AGEs seem to be key for both diabetes and normal blockade to the kidney? Dr. Fogo: I'm not aware of such efforts. Anecdotally, aging, but aminoguanidine does not appear to be the best tool in humans for attacking this mechanism.
I know from my clinical biopsy practice that quite a number of nephrologists are treating proteinuric patients Dr. Harrington: Your first case was a patient with unilateral renal agenesis. The usual estimate is that 1 in 800 who are difficult to manage with higher than usual doses of an ACE inhibitor or with the combination of an ACE to 1000 people are born with a solitary kidney. I'll accept the data that perhaps these patients have a slightly higher inhibitor and an AT1 receptor antagonist and have not seen an excess of side effects, that is, hyperkalemia or risk of subsequent focal sclerosis and progressive renal failure, but the overwhelming majority of the patients in hypotension. I don't know whether those patients were selected for being low-risk patients. My clinical colfact do not develop progressive renal failure. What genetic or environmental factors should one look for in patients leagues who work directly with patients tell me that you cannot always return blood pressure to normal with who develop focal sclerosis? What are we missing?
Dr. Fogo: My hypothesis is that the risk of sclerosis single-drug therapy with an ACE inhibitor or a receptor antagonist. It appears to me that if blood pressure control in the remaining kidney depends on how normal that kidney is and whether the patient has been exposed to is our only goal, then we are vastly undertreating the end-organ damage and the fibrosis. We need to aim for extraordinary injuries. The spectrum of these congenital renal abnormalities seems quite broad. In many cases of maximal antifibrotic potential with our therapies. I would challenge us to do so and not just control blood pressure. unilateral renal agenesis, data suggest that the remaining kidney is not normal; these kidneys have larger glomeruli Dr. Samina Khan (Nephrology Fellow, Division of Nephrology, New England Medical Center): I was impressed than do kidneys in patients who had nephrectomy for trauma or disease later in life. It's possible that the rewith your data at the ASN meeting that showed regression of fibrosis. Are you aware of other glomerulonemaining kidney has a forme fruste of hypoplasia and decreased nephron number or abnormal development. That phritides in which reversal or regression of the fibrosis is observed, similar to the observation in diabetic patients? partly explains why these people are at excess risk compared to people who lose a kidney to trauma or surgery in Also, would you address the use of antifibrotic agents in chronic graft failure, in which advanced fibrosis is a adulthood. Polymorphisms that predict increased scarring are also being identified. The ACE D polymorphism, PAI major issue and the population has a higher morbidity rate and fewer treatment options? 4G and the TGF-␤ arginine 25 polymorphism would be of interest. Those polymorphisms could be markers of Dr. Fogo: In transplanted organs that have low-level glomerular lesions, notably, IgA deposits with mesangial patients whom we should follow more carefully.
Dr. Madias: I was very interested in the capillary expansion, these lesions can regress. An inadvertent experiment of transplanting a kidney with early diabetic branching for induction of regression of glomerulosclerosis. In other systems, the endothelial nitric oxide sysnephropathy into a normal patient demonstrated that diabetic lesions can regress in that setting, too. We don't tem appears to be important for endothelial migration, vascular remodeling, and angiogenesis. Is there any evihave a lot of data on other patients because we don't often perform repeat biopsies. dence for a role of the endothelial nitric oxide system in glomerular remodeling?
You asked about antifibrotic agents. Dr. Larry Hunsicker is heading a multicenter trial in patients with Dr. Fogo: We have given L-NAME to wild type or PAI-1 knockout mice to examine the contribution of chronic transplant nephropathy. One arm in this trial is treatment with an HMG CoA reductase inhibitor. The nitric oxide and PAI-1 in hypertensive injury. Our data show a link between nitric oxide and PAI-1 systems hypothesis is that this drug does not just improve hyperlipidemia, but that it has antifibrotic effects, maybe in that PAI-1 knockout animals were protected from perivascular fibrosis in response to L-NAME administrathrough Ras or geranyl-geranylation or other mechanisms. I did and it was developed based on experimental rat data.
7. Fogo A, Ichikawa I: Glomerular growth promoter: The common
The relevance of the rat data to humans was gratifying. 
